Clinical trials: Infection Reactivation
Severe Pneumonia
Herpes Simplex Virus Type 1 Infection/Reactivation of Patients With Severe Pneumonia（the HSV-SP Study）
Severe pneumonia(SP) is a one of the main causes of death for critically ill patients.Samples of bronchoalveolar lavage fluid (BALF) from SP patients often report positive for herpes simplex virus type 1 (HSV-1) DNA.
- Trial name
- NCT06936683
- Testing
- Bronchoalveolar Lavage (BAL) via Fiberoptic Bronchoscopy, throat Swab
- Volunteers
- 323 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Nasopharyngeal Cancinoma (NPC)
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Nearly all undifferentiated nasopharyngeal carcinoma (NPC) are associated with the Epstein-Barr Virus (EBV), which typically remains in a latent, non-immunogenic state within tumor cells.
- Trial name
- NCT07138989
- Testing
- Valganciclovir Hydrochloride Tablets, gemcitabine, cisplatin, and PD-1 antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Hepatitis B, Hepatocellular Carcinoma
The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma
This study aim to find out the risk of exacerbation of chronic hepatitis B after percutaneous radiofrequency ablation (RFA) or hepatectomy for HCC, and it's effect to treatment outcome.
- Trial name
- HBV-HCC (NCT00720668)
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Liver Transplantation (LT), Immuno-suppression
Immune Biomarkers for Predicting Complications After Liver Transplantation
This multicenter prospective observational study will evaluate immune biomarkers in adults undergoing liver transplantation. The study aims to describe how immune markers change before and after transplantation and to assess…
- Conditions
- Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection
- Trial name
- NCT07875595
- Testing
- Immune Biomarker Assessment
- Where
- 3 sites in Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Reactivation of Hepatitis B Virus
Chemotherapy Efficacy and Follow-up Study of Hepatitis B Virus Infection and Reactivation in Children With Leukemia
Children with clinically diagnosed leukemia may experience occult HBV infection after chemotherapy immunosuppressive therapy, which may affect the normal course of leukemia treatment.
- Trial name
- NCT03529760
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Infectious Complications Following HSCT
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
DESIGN: Disease registry - non-interventional. INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.
- Trial name
- EPROS (NCT02873325)
- Testing
- antiviral therapies for CMV and/or ADV
- Where
- 2 sites in United Kingdom
- Volunteers
- 1 people
- Sponsor
- Cell Medica Ltd
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
Tracheobronchitis, Herpes Simplex Infection
Bronchoscopic Score for Prediction of Herpes Simplex-virus Type 1 (HSV-1) Reactivation
Tracheobronchial reactivation of HSV-1 is a common finding in critically ill patients and is associated with longer intensive care unit (ICU) stay and mechanical ventilation.
- Trial name
- NCT05331417
- Testing
- Patients with herpes-simplex infection requiring bronchoscopy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Muenster
Epstein-Barr Virus (EBV), Healthy Volunteers
A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
This multi-center, prospective, longitudinal cohort study is designed to gather immunological and clinical data on EBV reactivation in EBV seropositive adults aged 18 to 29 years.
- Trial name
- NCT07536048
- Testing
- Investigational Procedure
- Where
- 2 sites in Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hiv
Study of the Effects of Farnesoid X Receptor (FXR) Ligands on the Reactivation of Latent Provirus
The Farnesoid X receptor (FXR) is a nuclear receptor that controls the transcription of many genes involved in lipid and glucose metabolism.
- Trial name
- FXReservoir (NCT03618862)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Hospices Civils de Lyon
Congenital Cytomegalovirus Infection, Cytomegalovirus Infection Reactivation
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
The purpose of this study is to assess the risk of congenital cytomegalovirus (cCMV) infection in newborns born to seropositive women.
- Trial name
- NCT02645396
- Where
- 2 sites in China
- Volunteers
- 8,855 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Cytomegalovirus Infection Reactivation
Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
To explore the effect of letermovir prophylaxis on cytomegalovirus-specific immune reconstitution post unrelated cord blood transplantation
- Trial name
- NCT06441669
- Testing
- Letermovir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Provincial Hospital
CMV, AdV Infection
Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone
Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.
- Conditions
- CMV, AdV Infection, AdV Reactivation, Adenovirus
- Trial name
- NCT07225972
- Testing
- Standard of Care Antiviral medications, Viral CTLs
- Where
- 2 sites in United States
- Volunteers
- 138 people
- Sponsor
- New York Medical College
Genital Herpes
A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation
We propose to study the episode rate, duration, and quantity of HSV-2 genital shedding in patients taking standard, FDA approved, CDC recommended doses of acyclovir (400 mg PO BID) for HSV-2 suppression compared to taking no…
- Trial name
- NCT00723229
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Washington
HIV I Infection
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir
The REDUC trial's objective is to address one of the core issues with the treatment of HIV, which is that some HIV infected cells hide in so-called latent reservoirs.
- Trial name
- REDUC (NCT02092116)
- Testing
- Romidepsin, Vacc-4x, rhuGM-CSF
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Bionor Immuno AS
Acute Lung Injury, Acute Respiratory Distress Syndrome
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Trial name
- GRAIL (NCT01335932)
- Testing
- IV Ganciclovir
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
CMV Infection or Reactivation After Allogenic HSCT
CMV-TCR-T Cells for CM Virus Infection After HSCT
This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.
- Trial name
- NCT04153279
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Hebei Yanda Ludaopei Hospital